Company Description
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders.
The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).
Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD.
The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist.
It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America.
NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
| Country | Switzerland |
| Founded | 2015 |
| IPO Date | Jan 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Alexander Zwyer |
Contact Details
Address: The Circle 6 Zurich, 8058 Switzerland | |
| Phone | 41 44 512 21 50 |
| Website | nlspharma.com |
Stock Details
| Ticker Symbol | NLSP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.15 |
| CIK Code | 0001783036 |
| CUSIP Number | H57830103 |
| ISIN Number | CH0523961370 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander Zwyer M.B.A. | Chief Executive Officer and Director |
| Dr. Eric Konofal M.D., Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. George Apostol M.D. | Chief Medical Officer and Global Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 27, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Aug 26, 2024 | 6-K | Report of foreign issuer |
| Aug 15, 2024 | 6-K | Report of foreign issuer |
| Aug 14, 2024 | 6-K | Report of foreign issuer |
| Jul 30, 2024 | 6-K | Report of foreign issuer |
| Jul 15, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 1, 2024 | 424B5 | Filing |
| Jul 1, 2024 | 6-K | Report of foreign issuer |
| Jun 27, 2024 | 6-K | Report of foreign issuer |
| Jun 25, 2024 | EFFECT | Notice of Effectiveness |